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http://www.biomedcentral.com/1471-2369/13/171RESEARCH ARTICLE Open AccessImpact of heavy proteinuria on clinical outcomes
in patients on incident peritoneal dialysis
Seok Hui Kang, Kyu Hyang Cho, Jong Won Park, Kyung Woo Yoon and Jun Young Do*Abstract
Background: There are few reports on the nutritional status changes and residual renal function (RRF) according to
proteinuria levels in patients on peritoneal dialysis (PD).
Methods: A total of 388 patients on PD were enrolled. The patients were divided into 3 groups with
respect to initial proteinuria: the A (n = 119; <500 mg/day), B (n = 218; 500–3,500 mg/day), and C groups
(n = 51; >3,500 mg/day).
Results: The patients with higher proteinuria levels had a higher incidence of male sex, diabetes mellitus, and
icodextrin use than those with lower proteinuria levels. Although initial peritoneal albumin loss in C group was
lower than that detected in the other groups, no significant difference was observed in peritoneal albumin loss
among the 3 groups at the end of follow-up period. At the time of PD initiation, the Geriatric nutritional risk index
(GNRI) was lower in the C group than in the other 2 groups. However, at the end of the follow-up period, there
was no significant difference in GNRI between the 3 groups. The GNRI increased, and the proteinuria level or RRF
decreased more in the C group than in the other 2 groups. There were no significant differences in lean mass
index or fat mass index change from the time of PD initiation to the end of the follow-up period. However, fat
mass index and nPNA showed greater increases in the C group. The multivariate analysis revealed that proteinuria
was negatively correlated with GNRI at the time of PD initiation and at the end of the follow-up period. The initial
RRF and proteinuria were negatively correlated with the RRF decline during the follow-up.
Conclusion: The attenuation of the nephrotic proteinuria, along with the RRF decline, was associated with the
improvement of the malnutrition.
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Proteinuria is a widely known marker for glomerular/
tubulointerstitial disease, with increasing amounts of
urinary protein reflecting a greater intensity of kidney
injury [1]. Protein losses in the urine are usually com-
pensated for by increased albumin synthesis in patients
on peritoneal dialysis (PD) [2]. If protein loss exceeds
protein synthesis, malnutrition develops. In addition,
proteinuria has been shown to play direct and indirect
roles in the deterioration of renal function [1].
Residual renal function (RRF) has consistently been a
prognostic factor in patients on PD [3-5]. RRF has been
associated with multiple beneficial effects, including* Correspondence: jydo@med.yu.ac.kr
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reproduction in any medium, provided the orblood pressure control, increased sodium concentration
or fluid removal, increased middle molecule clearance,
and better nutritional status [6]. RRF loss is associated
with malnutrition via increased energy expenditure and
poorer appetite.
Jansen et al. showed that greater urinary protein loss
is a risk factor of rapid RRF decline in patients on dialy-
sis [7]. High proteinuria levels in patients on PD are
associated with malnutrition and a rapid RRF decline.
Over time, patients on PD with high proteinuria levels
develop a rapid RRF decline, but their degrees of malnu-
trition may be improved owing to decreased renal pro-
tein loss by the RRF reduction. However, there are few
reports on the nutritional status changes and RRF
according to proteinuria levels in patients on PD.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Selection of patients
We reviewed the medical records at the Yeungnam Uni-
versity Hospital in Korea and identified 566 patients
(>18 years of age) who received PD between January
1997 and May 2011. We excluded 57 patients who had
initial oliguria (urine output <200mL/day), 97 patients
for whom data on nutritional status or proteinuria levels
were unavailable, and 24 patients with less than 1 year
of follow-up. A total of 388 patients were enrolled in
the study. The patients were divided into 3 groups
with respect to initial proteinuria level: the A (n = 119;
<500 mg/day), B (n = 218; 500–3,500 mg/day), and
C groups (n = 51, >3,500 mg/day). This study was
approved by the institutional review board of Yeungnam
University Hospital (YUH-12-0366-O35). The board
waived the need for informed consent.
Clinical information
The clinical and laboratory data collected at the time
of PD initiation included age, sex, underlying disease
of end-stage renal disease (ESRD), use of icodextrin or
renin-angiotensin (RAS) blockade, mean arterial pres-
sure (MAP; mmHg), peritoneal equilibration test (PET),
serum creatinine level (mg/dL), corrected calcium level
(mg/dL), phosphorus level (mg/dL), C-reactive protein
level (CRP; mg/dL), serum albumin level (g/dL), 24-hr
urine volume (mL/day), RRF (mL/min/1.73m2), weekly
Kt/V, peritoneal Kt/V, Geriatric nutritional risk index
(GNRI), dialysis modality (automated PD), 24-hr peri-
toneal albumin loss (mg/day), 24-hr proteinuria level
(mg/day), 24-hr dialysate glucose absorption (g/day),
lean mass index (kg/m2), and fat mass index (kg/m2).
The laboratory findings were measured every 6 months
after the initiation of PD during the first year. The pres-
ence of peritonitis was documented from patient records
during the first year. All patients with peritonitis were
treated with cefazolin sodium and tobramycin sulfate as
first-line antibiotics. For PET, the intra-abdominal fluid
was drained, and PD fluid containing 4.25% glucose was
infused intraperitoneally [8]. The creatinine level of the
drained dialysate 4 hours after the injection was divided
by that of blood to obtain the D/P Cr ratio. High trans-
porter was defined as more than 0.81 of D/P Cr ratio.
Weekly Kt/V was calculated using a 24-hr collection of
dialysate and urine. The distribution of volume of urea
was calculated with V, estimated from the previous study
[9]. Inadequate dialysis was defined as weekly Kt/V<1.7.
Dietary protein intake was calculated using the follow-
ing equation: protein equivalent of nitrogen appearance
(PNA) = 15.1 + 0.195 urea appearance (mmol/day) +
protein losses (g/day) [10]. Urea appearance rate and
protein losses were determined from the measured urea
and protein excretion in the dialysate and urine. PNAwas normalized for ideal body weight calculated using
Lorenz equations [11]. Corrected calcium level was
calculated on the basis of Payne’s formula as follows:
corrected calcium (mg/dL) = total calcium (mg/dL) +
0.8 × [4 – albumin (g/dL)] [12]. Peritoneal albumin
loss (mg/day), proteinuria level (mg/day), urine volume,
and RRF were measured via the 24-hr urine and dialysate
collection. The RRF was calculated from the 24-hr urine
sample collection as the mean of the renal creatinine and
urea clearances. The GNRI was calculated based on the
serum albumin level and body weight, using the follow-
ing equation: GNRI = [1.489 × albumin (g/L)] + [41.7 ×
(body weight / ideal body weight)] [13,14]. The ideal
body weight was calculated using the Lorentz equations
[11]. The ratio of body weight to the ideal body weight
was set at 1 when the body weight exceeded the ideal
body weight [13,15]. Lean and fat masses were measured
using dual X-ray absorptiometry (Hologic, Bedford, MA,
USA). The fat and lean mass indexes were calculated by
dividing the mass by the height squared. MAP was cal-
culated using the following formula: (2 × systolic blood
pressure + diastolic pressure)/3.Statistical methods
The data were analyzed using SPSS version 19 (SPSS,
Chicago, IL, USA). The distribution of the continuous
variables was checked using the Kolmogorov-Smirnov
test. The normally distributed variables were expressed
as mean (SD) and compared using a t test or one-way
analysis of variance (ANOVA). The nonparametric vari-
ables were expressed as median (range) and were com-
pared using the Mann–Whitney or Kruskal-Wallis test.
One-way ANOVA or Kruskal-Wallis test were followed
by a post hoc Tukey comparison or Bonferroni correc-
tion. The categorical variables were expressed as counts
and percentages and analyzed using the Pearson χ2 or
Fisher exact test. Correlation analysis was performed to
assess the strength of the relationship between two con-
tinuous variables. Univariate followed by multivariate
linear regression was used to determine the independent
predictors of the RRF decline. Values of P < 0.05 were
considered statistically significant.Results
Clinical characteristics at the time of PD initiation and the
end of the follow-up period
The mean patient age was 53.3 ± 14.5 years in the A
group, 53.3 ± 13.3 years in the B group, and 50.3 ± 12.6
years in the C group (P = 0.323; Table 1). The patients
with the higher proteinuria levels had a higher incidence
of male sex, diabetes mellitus (DM), and icodextrin use
than those with lower proteinuria levels. At the time of
PD initiation, the GNRI in the C group was lower than
Table 1 Comparison of the clinical characteristics according to the initial proteinuria level at the time of peritoneal
dialysis (PD) initiation and the end of the follow-up period
At the time of PD initiation A group (n=119) B group (n=218) C group (n=51) P value*
Age (years) 53.3 ± 14.5 53.3 ± 13.3 50.3 ± 12.6 0.323
Sex (male) 55 (46.2%) 123 (56.4%) 36 (70.6%) 0.012
Underlying disease <0.001
DM 34 (28.6%) 120 (55.0%) 39 (76.5%)
Hypertension 45 (37.8%) 49 (22.5%) 4 (7.8%)
Chronic glomerulonephritis 9 (7.5%) 18 (8.3%) 7 (13.7%)
Others 12 (10.1%) 13 (5.9%) 1 (2.0%)
Unknown 19 (16.0%) 18 (8.3%) 0
Use of icodextrin 28 (23.5%) 72 (33.0%) 24 (47.1%) 0.009
Use of renin-angiotensin blockade 101 (84.9%) 171 (78.4%) 46 (90.2%) 0.089
Creatinine level (mg/dL) 6.78 ± 2.54 6.80 ± 2.38 6.94 ± 2.88 0.923
Corrected calcium level (mg/dL) 9.05 ± 0.87 8.88 ± 0.79 8.93 ± 0.84 0.201
Phosphorus level (mg/dL) 3.85 ± 1.28 3.79 ± 1.16 4.05 ± 1.29 0.364
CRP level (mg/dL) 0.177 (0.00~4.52) 0.13 (0.00~4.44) 0.13 (0.02~3.28) 0.186
Dialysis modality (APD) 2 (1.7%) 29 (13.3%) 6 (11.8%) 0.002
PET 0.669
High transporter 17 (14.3%) 30 (13.8%) 7 (13.7%)
Others 99 (83.2%) 186 (85.3%) 44 (86.3%)
NA 3 (2.5%) 2 (0.9%) 0 (0%)
Weekly Kt/V 2.44 ± 0.90 2.39 ± 0.63 2.50 ± 0.69 0.604
Peritoneal Kt/V 1.75 ± 0.55 1.63 ± 0.47 1.64 ± 0.55 0.096
Inadequate dialysis dose 18 (15.1%) 27 (12.4%) 4 (7.8%) 0.677
Albumin level (g/dL) 3.59 ± 0.48b 3.53 ± 0.54b 3.05 ± 0.61a <0.001
GNRI 93.3 ± 7.7b 93.1 ± 8.42b 86.4 ± 9.2a <0.001
nPNA (g/kg/day) 0.88 ± 0.20 0.89 ± 0.18 0.90 ± 0.22 0.900
MAP 90 ± 13 92 ± 12 98 ± 12 0.080
Lean mass index (kg/m2) 15.92 ± 2.19a 16.53 ± 1.99a 17.91 ± 2.64b <0.001
Fat mass index (kg/m2) 5.23 ± 2.30 4.91 ± 2.26 4.78 ± 2.34 0.412
Urine volume (mL/day) 700 (200–2830)a 960 (200–3300)b 1100 (300–3700)b <0.001
RRF (mL/min/1.73 m2) 2.90 (0.33–34.30)a 3.49 (0.58–15.46) a 4.22 (1.50–23.41)b <0.001
Peritoneal albumin loss (mg/day) 3479 ± 1319a 3218 ± 1273a 2685 ± 993b 0.001
Proteinuria level (mg/day) 150 (39–490)a 1241 (504–3,458)b 5786 (3,510–24,000)c <0.001
Glucose absorption (g/day) 67.5 ± 19.2 65.4 ± 21.9 65.4 ± 24.8 0.676
At the end of follow-up
Creatinine (mg/dL) 7.80 ± 2.63a 8.50 ± 2.96a 10.43 ± 3.35b <0.001
CRP (mg/dL) 0.12 (0.00–3.98) 0.10 (0.00–5.82) 0.15 (0.00–3.75) 0.521
Weekly Kt/V 2.33 ± 0.69b 2.20 ± 0.64a,b 2.01 ± 0.50a 0.026
Peritoneal Kt/V 1.62 ± 0.39 1.55 ± 0.39 1.60 ± 0.39 0.326
Inadequate dialysis dose 7 (5.9%) 31 (14.2%) 10 (19.6%) 0.058
Albumin (g/dL) 3.80 ± 0.47b 3.63 ± 0.47a 3.59 ± 0.48a 0.008
GNRI 97.2 ± 7.2 94.8 ± 7.5 94.9 ± 7.3 0.122
nPNA (g/kg/day) 0.92 ± 0.19 0.94 ± 0.22 0.96 ± 0.19 0.641
MAP 95 ± 15a 96 ± 13a 107 ± 15b 0.006
Peritonitis rate (episodes/year) 0.32 ± 0.58 0.34 ± 0.58 0.27 ± 0.45 0.720
Lean mass index (kg/m2) 15.95 ± 2.32a 16.58 ± 2.14a 18.03 ± 2.10b <0.001
Fat mass index (kg/m2) 5.73 ± 2.32 5.58 ± 2.01 5.41 ± 2.30 0.770
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Table 1 Comparison of the clinical characteristics according to the initial proteinuria level at the time of peritoneal
dialysis (PD) initiation and the end of the follow-up period (Continued)
Urine volume (mL/day) 900 (0–2480)b 810 (0–2950)b 460 (0–1600)a 0.001
RRF (mL/min/1.73 m2) 3.11 (0.00–24.3)b 2.88 (0.00–17.26)b 1.41 (0.00–6.14)a 0.008
Peritoneal albumin loss (mg/day) 3028 ± 1057 3018 ± 1200 3174 ± 1277 0.606
Proteinuria level (mg/day) 258 (0–4000)a 636 (0–4911)b 995 (0–15600)b <0.001
The data are expressed as numbers (percentages) for the categorical variables and median (range) or mean ± standard deviation for the continuous variables.
*Statistical significance was tested by one-way analysis of variance or Kruskal-Wallis test for the continuous variables and Pearson χ2 test or Fisher exact test for
the categorical variables. The different superscripts (a,b,c) indicate significant differences from each other using post hoc Tukey comparison or Bonferroni
correction.
DM, diabetes mellitus; CRP, C-reactive protein; APD, automated peritoneal dialysis; PET, peritoneal equilibration test; NA, non-available; GNRI, geriatric nutritional
risk index; nPNA, normalized protein equivalent of nitrogen appearance; MAP, mean arterial pressure; RRF, residual renal function.
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follow-up period, there was no significant difference in
GNRI among the 3 groups. The increases in GNRI and
decreases in proteinuria levels or RRF in the C group
were greater than those in the other 2 groups (P < 0.001;
Table 2). At the time of PD initiation, the lean mass
index in the C group was greater than that in the other
2 groups (P < 0.001). There was no significant difference
in lean mass index change from the time of PD initiation
to the end of the follow-up period. At the end of the
follow-up period, weekly Kt/V in the C group was lower
than that in the A group (P = 0.026). However, there
was no significant difference in peritoneal Kt/V at either
the time of PD initiation or the end of the follow-up
period. Although the peritoneal albumin loss was less in
the C group than in the other groups at the time of PD
initiation, no significant differences were observed in the
peritoneal albumin loss at the end of follow-up period.
There was no significant difference in change from the
time of PD initiation to the end of the follow-up period.
Factors affecting GNRI and RRF decline
To identify the relevance of the variables affecting GNRI
and RRF decline, clinical and laboratory parameters were
analyzed using univariate and multivariate regressionTable 2 Changes in the variables from the time of peritoneal
comparison of the 3 groups according to initial proteinuria le
A group
Delta GNRI 3.47 ± 6.54a
Delta RRF (mL/min/1.73 m2) 0.00 (−9.99 to 7.10)a
Delta nPNA 0.04 ± 0.23
Delta MAP 4.4 ± 16.3
Delta total lean mass index 0.47 ± 1.19
Delta total fat mass index 0.76 ± 1.03
Delta peritoneal albumin loss (mg/day) −233 ± 995
Delta proteinuria (mg/day) 197 ± 648a
The data are expressed as numbers (percentages) for the categorical variables and
*Statistical significance was tested by one-way analysis of variance or Kruskal-Wallis
for the categorical variables. The different superscripts (a,b,c) indicate significant diff
correction.
GNRI, geriatric nutritional risk index; RRF, residual renal function; nPNA, normalizedmodels (Table 3 and Table 4). The univariate and multi-
variate analyses revealed that age, DM, and proteinuria
were negatively correlated with GNRI at the time of PD
initiation. At the end of the follow-up period, age, DM,
peritoneal albumin loss, proteinuria, and RRF were asso-
ciated with GNRI. The initial RRF and proteinuria levels
were negatively correlated with RRF decline during the
follow-up. Notably, there was no significant association
between RRF decline and MAP at PD initiation.
Discussion
This study demonstrates that a high proteinuria level is
associated with malnutrition and rapid RRF or urine vol-
ume decline. A simultaneous decline in proteinuria level
and RRF or urine volume appears to improve initial low
GNRI. However, the RRF and urine volume decline led
to decreased dialysis adequacy.
Proteinuria is a well-documented risk factor for the
progression of chronic kidney disease in patients who
are not treated with dialysis [16]. However, the specific
effects of proteinuria level on RRF in patients on dialysis
remain elusive. Jansen et al. showed that greater urinary
protein loss is negatively associated with RRF [7]. How-
ever, using multivariate analysis, another study did not
show that 24-hr proteinuria is associated with a fasterdialysis initiation to the end of follow-up period:
vels
B group C group P value*
1.92 ± 6.63a 6.97 ± 8.52b <0.001
−0.81 (−7.88 to 6.58)a −2.41 (−23.41 to 2.31)b <0.001
0.05 ± 0.23 0.06 ± 0.24 0.898
3.2 ± 17.1 8.6 ± 15.4 0.483
0.10 ± 1.23 −0.07 ± 2.56 0.198
0.75 ± 1.87 1.20 ± 1.49 0.418
−59 ± 1370 324 ± 1477 0.075
−475 ± 945a −4626 ± 5466b <0.001
median (range) or mean ± standard deviation for the continuous variables.
test for the continuous variables and the Pearson χ2 test or Fisher exact test
erences from each other using post hoc Tukey comparison or Bonferroni
protein equivalent of nitrogen appearance; MAP, mean arterial pressure.
Table 3 Predictive factors affecting the Geriatric nutritional risk index at the time of peritoneal dialysis (PD) initiation
and the end of the follow-up period
At the time of PD initiation Univariate Multivariate
Standardized β ± SE P value Standardized β ± SE P value
Age (years) −0.142 ± 0.033 0.006 −0.115 ± 0.032 0.022
Use of icodextrin 0.031 ± 0.941 0.552 - -
Sex (female) 0.014 ± 0.889 0.782 - -
DM −0.265 ± 0.852 <0.001 −0.185 ± 0.882 <0.001
Peritoneal albumin loss (mg/day) −0.021 ± 0.000 0.683 - -
RRF (mL/min/1.73 m2) 0.051 ± 0.150 0.327 - -
Proteinuria level (mg/day) −0.290 ± 0.000 <0.001 −0.250 ± 0.000 <0.001
At the end of follow-up
Age (years) −0.176 ± 0.032 0.003 −0.208 ± 0.031 <0.001
Use of icodextrin 0.062 ± 0.906 0.291 - -
Sex (female) 0.007 ± 0.880 0.899 - -
DM −0.291 ± 0.839 <0.001 −0.177 ± 0.864 0.003
Peritoneal albumin loss (mg/day)* −0.207 ± 0.000 <0.001 −0.204 ± 0.000 <0.001
RRF (mL/min/1.73 m2)* 0.189 ± 0.151 0.001 0.212 ± 0.145 <0.001
Proteinuria level (mg/day)* −0.143 ± 0.000 0.016 −0.143 ± 0.000 0.014
*The values are presented as findings at the end of the follow-up.
SE, standard error; DM, diabetes mellitus; RRF, residual renal function.
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teinuria levels in patients on PD are associated with a
rapid RRF decline. In this study, the RRF decline was
0.00 (−9.99 to 7.10) mL/min/1.73 m2 in the A group and
−0.81 (−7.88 to 6.58) mL/min/1.73 m2 in the B group; in
contrast, it was −2.41 (−23.41 to 2.31) mL/min/1.73 m2
in the C group. Although RRF decline occurred in the B
and C groups, the RRF in the patients with high protein-
uria levels tended to show a steeper decline. The multi-
variate regression analysis showed similar results.
Malnutrition is associated with mortality and morbid-
ity in patients on dialysis [18]. Hypoalbuminemia or pro-
tein energy wasting in PD patients is related to increased
catabolism, decreased protein synthesis, and external
protein loss from peritoneum or urine [18-20]. ExternalTable 4 Predictive factors affecting the decline in residual ren
initiation to the end of the follow-up period
Univariate
Standardized β ± SE
Age 0.008 ± 0.012
Sex (female) 0.122 ± 0.321
Use of icodextrin −0.092 ± 0.333
DM −0.096 ± 0.321
MAP (mmHg)* 0.087 ± 0.018
RRF (mL/min/1.73m2)* −0.517 ± 0.045
Peritoneal albumin loss (mg/day)* −0.117 ± 0.000
Proteinuria level (mg/day)* −0.315 ± 0.000
* The values are presented as the findings at the time of peritoneal dialysis initiatio
MAP, mean arterial pressure; DM, diabetes mellitus; SE, standard error.protein loss can have an identical pathogenic effect on
nephrotic syndrome [20]. The loss of peritoneal protein
in PD patients averages 5 g/day [21,22]. One study
demonstrated that peritoneal protein loss is related to
mortality and malnutrition in patients on PD [20]. How-
ever, protein losses in the peritoneal effluent are usually
compensated for by increased protein synthesis [23].
Balafa et al. showed that baseline peritoneal albumin
and protein clearances are associated with comorbidities,
but this is not a risk factor for decreased survival per se
[22]. In the present study, the peritoneal albumin loss
was less in the C group than in the A group at the time
of PD initiation. High proteinuria levels are associated
with hypoalbuminemia, which may be associated with
decrease in peritoneal albumin loss. However, noal function (RRF) from the time of peritoneal dialysis
Multivariate
P value Standardized β ± SE P value
0.897 - -




<0.001 −0.505 ± 0.045 <0.001
0.050 - -
<0.001 −0.271 ± 0.000 <0.001
n.
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loss among the 3 groups at the end of follow-up period.
Compared with changes in proteinuria, those in periton-
eal albumin loss were small (delta peritoneal albumin
loss was −233 ± 995 mg/day in A group, –59 ± 1370 in
B group, and 324 ± 1477 mg/day in C group). These
data demonstrate the lack of a relationship between pro-
teinuria and peritoneal albumin loss. In linear regression,
the peritoneal albumin loss was negatively correlated
with the nutritional status at the end of the follow-up
period. Our data show that the initial nutritional status
was associated with proteinuria alone, that follow-up nu-
tritional status was associated with proteinuria and peri-
toneal albumin loss. High proteinuria levels may have a
greater effect on nutritional status than peritoneal albu-
min loss.
The patients on PD who had high proteinuria levels
showed rapid RRF decline and eventual improvement of
nutritional status. The GNRI scores increased from 86.4 ±
9.2 to 94.9 ± 7.3 in the C group. The C group demon-
strated a significantly higher initial protein loss in the
urine accompanied by malnutrition. However, the follow-
up GNRI was not significantly different between the C
group and the other 2 groups. The impact of the initial
high proteinuria level on malnutrition was attenuated,
along with a decreased RRF with increasing duration of
PD. The change in the serum albumin level was similar to
that in GNRI.
Preservation of RRF has been consistent independent
predictor of survival in patients on PD [3-5,24]. The
benefits include improved control of blood pressure and
anemia, removal of uremic toxin, superior phosphate
control, and dialysis adequacy [6]. Wang et al. showed
that RRF preservation is associated with better nutri-
tional status according to appetite improvement or the
removal of inflammatory mediators [24]. However, un-
controlled high proteinuria levels are related to malnu-
trition. In fact, patients with uncontrolled high
proteinuria levels who are not on dialysis could be trea-
ted with medical nephrectomy using iatrogenic nephro-
toxic drugs. This study shows that RRF combined with
heavy proteinuria is associated with malnutrition and
that a rapid RRF decline leads to improved nutritional
status. This study also shows that RRF declines lead to
decreased dialysis adequacy. Because there were no sig-
nificant differences in peritoneal Kt/V between the 3
groups at baseline or follow-up, the decline of the
weekly Kt/V may be associated with the decreased renal
clearance. However, there was no significant difference
in number of patients with inadequate dialysis.
Previous studies have shown that RRF loss is asso-
ciated with malnutrition in patients on PD [24-26].
However, these studies have limitations that differ from
those of the present study. First, they had a cross-sectional design. Anuria or low RRF as a baseline char-
acteristic was associated with poor nutritional status, but
there are few data on the effects of RRF decline on nu-
trition. Second, patients were divided into groups
according to RRF status. Patients with heavy proteinuria
may be enrolled into groups along with patients with
RRF. If patients with RRF were divided into groups with
respect to proteinuria, subgroup analyses may show
similar results. The present study had an observational
design and simply monitored changes in RRF status.
Patients with RRF were divided into 3 groups according
to proteinuria status.
The patients with nephrotic syndrome and normal
renal function have increased protein synthesis rates but
inadequate responses to normalized serum albumin
levels [27]. Patients on dialysis also experience increased
protein synthesis in response to protein loss, but the re-
sponse to protein loss in patients on dialysis is greater
than that in patients with nephrotic syndrome and nor-
mal renal function [2,28]. Therefore, this malnutrition
change may be more closely associated with increases in
protein catabolic rate than renal function. The present
study did not show whether the nutritional improvement
in patients on PD with nephrotic-range proteinuria
levels is associated with changes in protein catabolic rate
or decreases in proteinuria levels. Further investigations
are needed to determine the definite association between
improved nutrition and RRF decline or decreased pro-
teinuria levels.
In the present study, MAP was not associated with a
decline in RRF, and at the end of the follow-up period,
MAP in C group was higher than that in the other
groups. Previous studies have shown that MAP in the
post-dialysis period is not associated with a decline in
RRF in patients on PD [29,30]. However, diastolic blood
pressure at predialysis period is related to decline in RRF
[7]. The relation between blood pressure and RRF remains
controversial. The higher MAP observed in C group at
the end of follow-up period may be associated with rapid
decline in RRF or underlying disease (high incidence of
DM in the C group). In our cohort, MAP at the end of
the follow-up period was 102 ± 14 mmHg in patients
with RRF < 1 mL/min/1.73m2 and 97 ± 12 mmHg in
those with RRF ≥ 1 mL/min/1.73m2 (P = 0.020). The
RAS blockade is a well-known therapeutic target asso-
ciated with RRF preservation [6]. Most patients in the
present study received a RAS blockade, and we were un-
able to analyze the association between RAS blockade
use and RRF decline.
It is important to evaluate whether aminoglycoside use
is associated with RRF decline in patients on PD. Some
previous studies have shown variable results regarding
the association between aminoglycoside use and rapid
RRF decline [17,31,32]. A multicenter study recently
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peritonitis was not associated with a rapid RRF decline
[33]. In present study, all patients with peritonitis
received aminoglycoside as first-line antibiotics. There
was no significant difference in peritonitis rate or amino-
glycoside use among the 3 groups. Investigations that
enroll only patients with peritonitis are needed to deter-
mine the effect of aminoglycoside on RRF decline.
Serum albumin is not the gold standard of nutrition in
patients on PD [34]. Serum albumin is greatly influenced
by variable factors such as malnutrition, hydration sta-
tus, and inflammation. This variable is included in the
GNRI equation. Therefore, it is difficult to consider
GNRI as a reliable measure of nutrition in patients with
heavy proteinuria levels. At the time of PD initiation, the
differences in GNRI among the 3 groups may be not
associated with nutritional status. The present study
shows data for nPNA, lean mass index, and fat mass
index using DEXA. The lean mass index in the C group
was greater than that in the other 2 groups at the time
of PD initiation and the end of the follow-up period.
However, there was no significant difference in lean
mass index change from the time of PD initiation to the
end of the follow-up period. However, because overhy-
dration causes overestimation of lean mass by DEXA,
the initial lean mass levels in C group may have been
overestimated. Therefore, the increases in lean mass in
C group may be higher than those in the other groups.
There was no significant difference in fat mass index
among the 3 groups, but we did detect a greater increase
in fat mass index in the C group (delta fat mass index:
of 0.76 ± 1.03, 0.75 ± 1.87, and 1.20 ± 1.49 in the A, B,
and C groups, respectively). The same trend was seen in
nPNA.
Conclusion
The high proteinruia level at PD initiation was asso-
ciated with rapid RRF decline. The attenuation of the
nephrotic proteinuria, along with the RRF decline, was
associated with the improvement of the malnutrition.
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